Substance / Medication

Telbivudine

Overview

Active Ingredient
telbivudine
RxNorm CUI
474128

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

198 trials linked to this intervention

198
Total Trials
24
Recruiting
66
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis.
Wu Xiaolu, Cai Shaohang, Li Zhandong et al. · Virol J · 2016
PMID: 27062520Meta-AnalysisFull text (PMC)
Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis.
Liu Hmin, Wang Xbo, Wan Gang et al. · Am J Med Sci · 2014
PMID: 23563307Meta-Analysis
Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis.
Lu Yong-Ping, Liang Xu-Jing, Xiao Xiao-Min et al. · Clin Lab · 2014
PMID: 24779291Meta-Analysis
[Efficacy and safety of telbivudine treatment to block mother-to-child transmission of hepatitis B virus: a meta-analysis].
Xu He-xiangg, Wang Li-juan, Yu Ya-xin et al. · Zhonghua Gan Zang Bing Za Zhi · 2012
PMID: 23207336Meta-Analysis
Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su Qi-Min, Ye Xiao-Guang · World J Gastroenterol · 2012
PMID: 23180951Meta-AnalysisFull text (PMC)
Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission.
Sun Weihui, Zhao Shangfei, Ma Lei et al. · BMC Gastroenterol · 2017
PMID: 28407735RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telbivudine (substance)
SNOMED CT
425347005
UMLS CUI
C1453933
RxNorm CUI
474128

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
198
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.